| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 46.52 | 12.6% | |
| Total Income | 57.10 | 20.1% | 1382.2% |
| Expenditure | 37.87 | 8.7% | 1144.7% |
| PBT | 19.23 | 51.2% | 2274.2% |
| Net Profit | 14.88 | 55.5% | 1737.1% |
| OPM | 27.07% | 3.28pp | |
| NPM | 26.06% | 5.93pp | 5.04pp |
| EPS | 0.79 | 46.3% | 618.2% |
Consolidated growth masks standalone revenue cliff; guidance credibility unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 3/10
Grade C
No prior guidance filed. Consolidated metrics (₹417 Cr) vs delivered standalone (₹46.5 Cr) create 9x unexplained variance.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Order book and M&A strategy suggest multi-year structural upside (FY27-FY28 margin expansion via UK/India integration, defense exports ramp). BUT standalone revenue ₹46.5 Cr contradicts mgmt's consolidated ₹417 Cr claim by 9x; QoQ decline -87.6% vs claimed +11% growth raises critical credibility questions. Guidance unproven; no track record. Risk: consolidation adjustments, execution delays in facilities, margin headwinds.
₹46.5 Cr
Revenue · +null% YoY₹14.9 Cr
Reported PAT · +2559.8% YoYExpanding
Margins · vs guidance: ContradictedDid the claims hold up?
Q2 operational revenue INR417 Cr, 11.43% QoQ growth from 374 Cr Q1
MISSDelivered Q2 revenue ₹46.5 Cr, down 87.6% QoQ
Q2 PAT INR48.6 Cr (ex-associates), up from Q1's 35.41 Cr
MISSDelivered Q2 PAT ₹14.9 Cr; standalone profitability far below claim
Order book ~10,000+ Cr, 90% international, strong visibility
UnverifiedUnverified from filings; management provided no segment breakdowns despite analyst requests
FY27 revenue guidance INR1,900-2,000 Cr
OVERSTATEDGuidance not yet testable; prior guidance none on record. Standalone trajectory suggests target wildly optimistic.
Earnings quality
What changed since the last call
Order book consolidation
UpgradeH1 FY27 new order wins ₹3,915 Cr (vs no prior guidance); defense order book ₹2,700 Cr executable over 5-7 years.
Capacity utilization baseline
DowngradeAerospace only 15% utilized, ammunition 20%, post-acquisition. Implies prior standalone ops much smaller.
Profitability scale
DowngradeStandalone Q2 PAT ₹14.9 Cr vs mgmt claim ₹48.6 Cr; acquisition contribution not separated.
The Q&A
Moderate. Analysts pressed on capex requirements (answered: adequate, no more capex needed), manufacturing facility split (answered: 30-70 UK-India split), and capacity utilization (answered: 10-15% CCT post-ramp). Management withheld customer breakdowns (NDA), facility-level financials, and acquisition details. Confidence in Q&A: neutral-to-cautious; evasion on key metrics.
Post-acquisition capex & margins — Nilesh Soni, Haitong Securities
Answered₹8-9M capex invested; improvements in on-time-in-full (OTIFs 65→97%), buffer stock, equipment kits. 200% per-quarter improvement in UK EBITDA margin.
M107 shells revenue recognition — Ronak Singhvi, NAFA Asset Managers
Answered85% already recognized in Q1-Q2; 15% completion in Q3. Supplied to Indrajal for 155mm shells order.
Defense manufacturing facility capacity — Dipen Vakil, Phillip Capitals
AnsweredAerospace 15%, ammunition ~20%. No more capex; facility good for next few years. Sri City ramp to 50-60% by Q4, 100% by FY29.
Aerospace order book delivery cadence — Dipen Vakil, Phillip Capitals
PartialLong-term executable contracts, stable high-visibility. UK execution 15-20% annual growth, 15% per quarter ramp.
Fundraise purpose and timing — Rajesh Joseph, Individual Investor
AnsweredFuel M&A growth; expected Q4 close, subject to shareholder approval, etcetera.
Defense vs aerospace revenue split — Jai Mendratta, Nirmal Bang
PartialYes, domestic defense strategic focus; will continue to grow. Defense order book ₹2,700 Cr.
Export revenue and geographic footprint — Varun Kulkarni, InCred Capital
Partial~90% revenue export between UK and India. Cannot disclose customer breakdowns due to NDAs.
Aeropsace margin expansion mechanics — Tejash, T&J Investments
PartialWork transfer from UK to India, automation capex payoff, scale in India. 25-30% EBITDA margin by FY28 possible.
CCT facility utilization forecast — Tejash, T&J Investments
Answered10-15% post-ramp start. Every quarter ~10% increase. 50-60% by FY28 end.
Debt and working capital — Devang, Spark PMS
AnsweredDebt ~₹80 Cr, mostly working capital. Term borrowings low; payback Jan-Dec FY27 per agreement. Debt-light balance sheet.
Guidance
FY27 revenue ₹1,900-2,000 Cr (consolidated target)
LowNo prior guidance to validate. Requires H2 sustain of ₹417 Cr run-rate (8 quarters forward at ~₹500 Cr per quarter). Standalone trajectory suggests external reliance on M&A consolidation only.
EBITDA margin ~20% FY27; expand 200-400 bps by FY27 end, 400-600 bps by FY28 end (25-30% aerospace target)
MediumMechanism credible (UK automation capex payoff, India work transfer, scale). But execution risk high on work-to-India logistics & labor ramp. Current aerospace EBITDA 22-30% range; defense margins higher.
No additional capex required; prior investments sufficient for next few years
HighSri City facility built; UK capex (automation) already deployed. Only work-transfer & incremental shifts needed.
Risks the call surfaced
Revenue reporting discrepancy
HighMgmt claims ₹417 Cr Q2 revenue; delivered standalone ₹46.5 Cr. 9x gap suggests heavy M&A reliance and weak organic core.
Standalone revenue contraction
HighQ2 standalone revenue ₹46.5 Cr down 87.6% QoQ (implied Q1 ~₹354 Cr). Suggests core Indian operations under stress or major project completion skew.
M&A integration execution
HighNasmyth was in financial distress pre-acquisition; Bromford integration unproven. Target margin expansion (200-400 bps FY27, 400-600 bps FY28) depends on successful automation, work transfer, cultural fit.
Customer concentration
High90% of revenue from export contracts with major OEMs (Rolls-Royce, Airbus, Lockheed, BAE Systems). Loss of single customer or contract deferral has outsized impact.
Capex deployment risk on Sri City
MediumSri City facility (operational Sept 2026) targeting 50-60% utilization by FY28. If order intake fails or ramp stutters, capex stranding and margin compression.
Fundraise delay or shortfall
Medium₹3,000 Cr fundraise for inorganic growth expected Q4 close. Shareholder approval, market conditions, regulatory delays could derail M&A pipeline.
Management
Score 6/10. Confident on strategy and order book, but evasive on segment metrics. Withheld customer breakdowns (NDA), facility-level financials, and capex detail. Avoided detailed P&L reconciliation between standalone and consolidated. Mixed. Achieved OTIF ramp (65→97% Nasmyth), on-time delivery to Rolls-Royce, repeat orders. But Q2 standalone revenue ₹46.5 Cr contradicts consolidated ₹417 Cr claim; execution on India manufacturing scale still nascent (Sri City Sept 2026 start).
1 · Q3/Q4 FY27
Defense order ramp-up expected Q3-Q4; new Indrajal BSF contract delivery
2 · H2 FY27
Sri City facility capacity ramp to 50-60%; 155mm shells production scaling
3 · Q4 FY27
M&A completion expected (target Q4); ₹3000 Cr fundraise ongoing
Risk: consolidation adjustments, execution delays in facilities, margin headwinds.